Softwr

Research · head to head

Genedata vs Greenphire

Genedata logo

Genedata

Research

Enterprise R&D data platforms for biologics, screening and bioprocess, owned by Danaher

From
On request
Rated
-
Full reviewWebsite
Greenphire logo

Greenphire

Research

Clinical trial participant payments, reimbursement and travel, now part of Suvoda

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Genedata there is no entry level and no published price at any tier, so a mid-sized biotech cannot even establish whether Genedata is in its range without a lengthy sales engagement.; Greenphire the standalone greenphire.com site now redirects to Suvoda and the brands have been integrated, so buyers are contracting with a randomisation and supply vendor and should expect cross selling rather than an independent payments specialist.
  • They diverge on capability: Genedata covers Screener, Greenphire covers ClinCard.
  • Prices and features above were last checked on 31 August 2026.

Where they differ

Only the attributes on which Genedata and Greenphire actually diverge.

Attributes where Genedata and Greenphire differ
AttributeGenedataGreenphire
PlatformsWeb, On-premise, Private cloudWeb, iOS, Android

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Research).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Genedata

  • Screener
  • Biologics
  • Bioprocess
  • Expressionist
  • Selector
  • Profiler
  • Instrument integration
  • GxP-capable deployments

Only in Greenphire

  • ClinCard
  • Direct to bank payment
  • Expense reimbursement
  • Travel and logistics
  • Site payments
  • Budgeting and benchmarking
  • Tax handling

What people use each for

The jobs each tool is most often brought in to do.

Genedata

  • A pharmaceutical screening group processing thousands of plates a week where manual QC and curve fitting no longer scalenot Greenphire
  • A biologics discovery team linking antibody sequence, expression and assay data across a campaign instead of in spreadsheetsnot Greenphire
  • A process development group standardising bioprocess run data across sites for modelling and scale-upnot Greenphire
  • A CRO delivering high-throughput screening results to sponsors that require documented, reproducible analysis pipelinesnot Greenphire

Greenphire

  • A global Phase III trial paying stipends across many countries where participants cannot practically be reimbursed by sponsor accounts payablenot Genedata
  • A decentralised or hybrid trial where participants travel long distances and the sponsor funds flights and accommodationnot Genedata
  • A trial in a population where slow reimbursement drives dropout and same day payment materially helps retentionnot Genedata
  • A sponsor that wants site payment milestones and participant payments handled by one vendor rather than twonot Genedata

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Genedata

  • There is no entry level and no published price at any tier, so a mid-sized biotech cannot even establish whether Genedata is in its range without a lengthy sales engagement.
  • Platforms are licensed individually and most organisations need two or three, so the real contract is a sum of separate licences plus the integration work between them.
  • Deployment is a services programme rather than an installation, running months and requiring scientific configuration by the vendor, which means value arrives long after the first invoice.
  • Danaher ownership since 2023 gives the roadmap a natural pull toward Danaher instrument and bioprocessing lines, which is an advantage on that hardware and a question to ask if your instrument estate is from competitors.
  • Validated deployments for regulated use add scope, cost and an ongoing revalidation obligation on your side after each vendor release, and that recurring internal effort is rarely counted in the business case.

Greenphire

  • The standalone greenphire.com site now redirects to Suvoda and the brands have been integrated, so buyers are contracting with a randomisation and supply vendor and should expect cross selling rather than an independent payments specialist.
  • Nothing is published on price, and the typical shape of a platform fee plus per participant and per transaction charges means the cost of a trial is not knowable until enrolment is known.
  • Payment method availability varies sharply by country, so a global protocol may end up with card payments in some regions and slow manual processes in others, which undermines the retention argument that justified the purchase.
  • Sites bear the administrative work of enrolling participants and triggering payments but are not the buyer, so adoption depends on the sponsor mandating it and site resistance is a real implementation risk.
  • Participant payments create tax reporting obligations that differ per jurisdiction, and the tooling helps but does not remove sponsor liability, so legal and finance review is required in every country the trial runs in.

Pricing, plan by plan

Genedata

On request
  • Genedata platform licence$undefined/year
    • Each platform, such as Screener or Biologics, licensed separately
    • Annual enterprise subscription scoped on users, sites and data volume
    • Implementation and scientific configuration services quoted as a separate programme

Greenphire

On request
  • Greenphire Patient Payments$undefined/year
    • Priced per study through a sales process
    • Typically a platform fee plus per participant and per transaction charges
    • Funding of the payment float is separate from the software fee

Which should you pick?

Choose Genedata if

  • You need screener.
  • You work on Web, On-premise, Private cloud.
  • You also want biologics.
Genedata review

Choose Greenphire if

  • You need clincard.
  • You work on Web, iOS, Android.
  • You also want direct to bank payment.
Greenphire review

Questions people ask

Is Genedata or Greenphire better?
Neither clearly leads. Genedata starts at On request and Greenphire at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Genedata or Greenphire?
Genedata starts at On request and Greenphire at On request.
Does Genedata or Greenphire run on more platforms?
Genedata runs on Web, On-premise, Private cloud. Greenphire runs on Web, iOS, Android.
What is Genedata best used for?
Genedata is most often used for a pharmaceutical screening group processing thousands of plates a week where manual qc and curve fitting no longer scale, a biologics discovery team linking antibody sequence, expression and assay data across a campaign instead of in spreadsheets, a process development group standardising bioprocess run data across sites for modelling and scale-up, a cro delivering high-throughput screening results to sponsors that require documented, reproducible analysis pipelines. Of those, a pharmaceutical screening group processing thousands of plates a week where manual qc and curve fitting no longer scale and a biologics discovery team linking antibody sequence, expression and assay data across a campaign instead of in spreadsheets are not what Greenphire is typically brought in for.
What can Genedata do that Greenphire cannot?
Genedata covers Screener, Biologics, Bioprocess, Expressionist. Greenphire covers ClinCard, Direct to bank payment, Expense reimbursement, Travel and logistics.

Answered from the vendors’ own pages

Genedata: Who owns Genedata?

Danaher acquired the company in 2023. It remains headquartered in Basel and continues under the Genedata name.

Greenphire: Is Greenphire still sold?

Yes, as Greenphire Patient Payments on the Suvoda platform. The independent website and social presence have been consolidated into Suvoda.

Genedata: Is there a small-team or starter option?

No. Everything is an enterprise contract scoped by users, sites and data volume, with services attached.

Greenphire: What is ClinCard?

The reloadable debit card Greenphire issues to participants. Greenphire Patient Payments was formerly known as ClinCard.

Genedata: Do I buy one product or the whole suite?

Each platform is licensed separately. Most customers license two or three and integrate between them.

Greenphire: Does it publish pricing?

No. Pricing is per study and quoted through sales, and funding the payments themselves is separate from the software fee.

Genedata: Can it be used in a GxP environment?

Yes, with a validated deployment contracted as additional scope. Ongoing revalidation after releases remains your responsibility.

Greenphire: Can it pay participants outside the United States?

Yes, in more than thirty currencies, but the available payment method depends on the country.

Share

Related pages

More on Genedata

More on Greenphire

Keep looking

Other head to heads